RNS Number : 5438R
Shield Therapeutics PLC
09 March 2021

Shield Therapeutics plc
("Shield Therapeutics" or the "Company")

Australia's Therapeutic Goods Administration (TGA) approves Feraccru® to treat Iron Deficiency with or without anaemia in adults

London, UK, 9 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), notes that Australia's Therapeutics Goods Administration has registered Feraccru® in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults.

Feraccru® is already approved in the UK, European Union, Switzerland and United States for the treatment of iron deficiency with or without anaemia in adults. Norgine Pty Ltd will lead all marketing activities in Australia.

The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for medicinal products ("therapeutic goods").

For further information, please contact:

Shield Therapeutics plc +44 (0) 191 511 8500
Tim Watts (CEO)

Nominated Adviser and Joint Broker
Peel Hunt LLP +44 (0) 20 7148 8900
James Steel / Christopher Golden

Joint Broker
finnCap Ltd +44 (0) 20 7220 0500
Geoff Nash / Matthew Radley/ Alice Lane

Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne or shield@walbrookpr.com

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

REASSUFMAEFSEDD